Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial
ConclusionsFor patients with active PsA who are csDMARD-IR, risankizumab demonstrated durable long-term efficacy and was generally well tolerated, with a consistent long-term safety profile.Trial RegistrationClinicalTrials.gov identifier, NCT03675308.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | Clinical Trials | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Study